The authors report the 5-year follow-up data for the SOLO1 trial. Progression-free survival (PFS) was significantly longer with olaparib compared with placebo, and durable PFS benefits were seen with 2 years of maintenance olaparib therapy in patients with BRCA-mutated, newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer with a complete or partial response after platinum-based chemotherapy. Exploratory subgroup analysis showed that the use of maintenance olaparib resulted in a consistent PFS benefit over placebo in both higher-risk and lower-risk groups. Serious adverse events occurred in 21% of patients in the olaparib group versus 13% in the placebo group.
Maintenance olaparib should be considered the standard of care for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation.